Biocon Limited has informed the Exchange regarding a press release dated February 12, 2026, titled "Biocon Q3FY26 Operating Revenue at Rs 4,173 Cr Q3FY26 EBITDA at Rs 951 Cr Q3FY26 Net Profit at Rs 144 Cr ".
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Biocon Limited reported Q3FY26 operating revenue of Rs 4,173 crore, up 9% year-on-year, with total revenue at Rs 4,290 crore (up 11%). EBITDA grew 21% to Rs 951 crore with margins improving to 22%, while core EBITDA rose 21% to Rs 1,221 crore at 29% margins. Profit before tax (before exceptional items) jumped 64% to Rs 226 crore, and reported net profit surged 475% to Rs 144 crore. The Biosimilars segment grew 9% to Rs 2,497 crore, Generics surged 24% to Rs 851 crore, while CRDMO (Syngene) dipped 3% to Rs 917 crore. The company also completed the full integration of Biocon Biologics as a wholly owned subsidiary at a USD 5.5 billion valuation and raised Rs 4,150 crore via QIP in January 2026, taking cumulative equity raises to nearly USD 1 billion in eight months.
Strong operational performance with double-digit revenue and EBITDA growth, margin expansion, and significantly lower interest costs ahead should be positive for shareholders. The Biosimilars full integration simplifies the group structure and may support rerating, though the reported net profit includes large exceptional items tied to the Biocon Biologics share swap that warrant closer scrutiny.